ギラン・バレー症候群の世界市場レポート 2025年

ギラン・バレー症候群市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で7億9,000万米ドルに成長します。予測期間における成長の原動力は、ギラン・バレー症候群の有病率の上昇、気候変動の影響の拡大、免疫療法や薬剤の使用拡大、診断能力の向上、多巣性運動ニューロパチーの発生増加です。この期間に予想される主な動向には、診断技術の進歩、免疫グロブリン療法の開発、プラズマフェレーシス法の強化、遺伝子治療の探求、早期介入への重点化、予後のための新規バイオマーカーの同定、革新的治療のための臨床試験の拡大などがあります。

免疫疾患の有病率の上昇がギラン・バレー症候群市場の成長を牽引すると予想されます。免疫学的疾患は、免疫系が活動しすぎたり、活動しすぎなかったり、あるいは誤った方向に向かったりすることで発症し、自己免疫疾患、アレルギー、免疫不全などの症状を引き起こします。これらの疾患の増加は、環境の変化、生活習慣、診断能力の向上、遺伝的素因などの要因に影響されます。ギラン・バレー症候群は、身体の免疫系が誤って末梢神経を攻撃し、炎症や神経損傷を引き起こす自己免疫反応の結果として発症する可能性があります。例えば、2024年7月、スイスに本部を置く政府機関である国連合同エイズ計画（UNAIDS）の報告書によると、2022年末までに全世界で約3,950万人がHIVに感染し、同年に130万人が新たに感染し、63万人がエイズ関連で死亡したことが明らかになりました。2023年には、世界のHIV感染者数は約3,990万人に増加しました。その結果、免疫疾患のリスクの増大がギラン・バレー症候群市場に拍車をかけています。

ギラン・バレー症候群市場の主要企業は、治療効果を高め、アンメット・クリニカル・ニーズに対応し、市場での存在感を強化するために、モノクローナル抗体などの革新的な治療法の開発に注力しています。モノクローナル抗体は、特定の抗原を標的とするように設計された実験室で作製されたタンパク質であり、免疫反応を制御し、治療効果を向上させるのに役立ちます。例えば、2023年10月、米国のバイオ医薬品会社であるアネクソン社は、ギラン・バレー症候群の治療薬として開発したANX005について、欧州医薬品庁（EMA）から希少疾病用医薬品の指定を受けた。ANX005はC1qを標的とするモノクローナル抗体で、IVIgと比較して筋力の早期改善と人工呼吸の必要性の減少を示し、治療選択肢の重要な進歩を意味します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ギラン・バレー症候群 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のギラン・バレー症候群市場：成長率分析
• 世界のギラン・バレー症候群市場の実績：規模と成長, 2019-2024
• 世界のギラン・バレー症候群市場の予測：規模と成長, 2024-2029, 2034F
• 世界ギラン・バレー症候群総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のギラン・バレー症候群市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性炎症性脱髄性多発神経炎（AIDP）
• 慢性炎症性脱髄性多発根神経炎（CIDP）
• ミラー・フィッシャー症候群（MFS）
• 急性運動軸索性ニューロパチー（AMAN）
• その他のタイプ
• 世界のギラン・バレー症候群市場セラピューティクス社、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内免疫グロブリン（IVIG）
• 血漿交換
• その他の治療薬
• 世界のギラン・バレー症候群市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非経口
• オーラル
• 世界のギラン・バレー症候群市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 診断センター
• その他のエンドユーザー
• 世界のギラン・バレー症候群市場急性炎症性脱髄性多発神経炎（AIDP）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 古典的AIDP
• 自律神経障害を伴うAIDP
• 世界のギラン・バレー症候群市場慢性炎症性脱髄性多発根神経炎（CIDP）の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 進行性CIDP
• 再発寛解型CIDP
• 多巣性CIDP
• 世界のギラン・バレー症候群市場ミラーフィッシャー症候群（MFS）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 古典的なMFS
• 運動失調を伴うMFS
• 眼筋麻痺を伴うMFS
• 世界のギラン・バレー症候群市場急性運動軸索性ニューロパチー（AMAN）の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• クラシックAMAN
• 呼吸器系障害を伴うAMAN
• 世界のギラン・バレー症候群市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性感覚神経節症
• 脳神経障害を伴う変異
• ビッカースタッフ脳幹脳炎

第7章 地域別・国別分析

• 世界のギラン・バレー症候群市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のギラン・バレー症候群市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ギラン・バレー症候群市場：競合情勢
• ギラン・バレー症候群市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Merck & Co. Inc.
• Baxter International Inc.
• Biogen Inc.
• Horizon Therapeutics
• Octapharma AG
• Kedrion S.p.A.
• Annexon Inc.
• Immunovant Inc.
• CSL Behring LLC
• Hansa Biopharma AB
• NeuLine Health Inc.
• Ridge Diagnostics Inc.
• Deymed Diagnostic LLC
• VYVGART Hytrulo

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ギラン・バレー症候群市場2029：新たな機会を提供する国
• ギラン・バレー症候群市場2029：新たな機会を提供するセグメント
• ギラン・バレー症候群市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Guillain-Barre syndrome is a rare neurological condition in which the body's immune system mistakenly targets the peripheral nervous system. This results in muscle weakness, numbness, tingling, and, in severe cases, paralysis. While the exact cause remains unknown, it is often triggered by infections, such as respiratory or gastrointestinal infections, and occasionally by vaccinations or surgery.

The primary types of Guillain-Barre syndrome include acute inflammatory demyelinating polyneuropathy (AIDP), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Miller Fisher syndrome (MFS), acute motor axonal neuropathy (AMAN), among others. AIDP is an autoimmune condition in which the immune system attacks the myelin sheaths of peripheral nerves, leading to inflammation and demyelination. Treatment options for GBS include intravenous immunoglobulin (IVIG), plasma exchange, and other therapies. These treatments are primarily administered through parenteral and oral routes. The condition is managed in various healthcare settings, such as hospitals, clinics, diagnostic centers, and other medical facilities.

The guillain-barre syndrome market research report is one of a series of new reports from The Business Research Company that provides guillain-barre syndrome market statistics, including the guillain-barre syndrome industry's global market size, regional shares, competitors with a guillain-barre syndrome market share, detailed guillain-barre syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the guillain-barre syndrome industry. This guillain-barre syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The guillain-barre syndrome market size has grown strongly in recent years. It will grow from $0.60 billion in 2024 to $0.64 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to the increasing demand for GBS treatments, a rise in viral infections, expanding global vaccination campaigns, a better understanding of autoimmune mechanisms, and greater awareness and diagnosis.

The guillain-barre syndrome market size is expected to see strong growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The projected growth in the forecast period is driven by the rising prevalence of Guillain-Barre syndrome, the growing impact of climate change, the expanding use of immunotherapies and drugs, improved diagnostic capabilities, and the increasing occurrence of multifocal motor neuropathy. Key trends expected in this period include advancements in diagnostic techniques, the development of immunoglobulin therapies, enhancements in plasmapheresis methods, exploration of gene therapy, a stronger focus on early intervention, the identification of novel biomarkers for prognosis, and the expansion of clinical trials for innovative treatments.

The rising prevalence of immunological diseases is expected to drive the growth of the Guillain-Barre syndrome market. Immunological diseases occur when the immune system is either overactive, underactive, or misdirected, leading to conditions such as autoimmune disorders, allergies, or immunodeficiencies. The increase in these diseases is influenced by factors such as environmental changes, lifestyle habits, improved diagnostic capabilities, and genetic predisposition. Guillain-Barre syndrome can develop as a result of an autoimmune response in which the body's immune system mistakenly attacks the peripheral nerves, causing inflammation and nerve damage. For example, in July 2024, a report from the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, revealed that by the end of 2022, around 39.5 million people worldwide were living with HIV, with 1.3 million new infections and 630,000 AIDS-related deaths that year. By 2023, the global number of people living with HIV had increased to approximately 39.9 million. Consequently, the growing risk of immunological diseases is fueling the Guillain-Barre syndrome market.

Leading companies in the Guillain-Barre syndrome market are focusing on developing innovative therapies, such as monoclonal antibodies, to enhance treatment effectiveness, address unmet clinical needs, and strengthen their market presence. Monoclonal antibodies are lab-engineered proteins designed to target specific antigens, helping regulate immune responses and improve therapeutic results. For instance, in October 2023, Annexon Inc., a US-based biopharmaceutical company, received orphan drug designation from the European Medicines Agency (EMA) for its drug ANX005, developed for the treatment of Guillain-Barre syndrome. ANX005 is a monoclonal antibody targeting C1q, showing early improvements in muscle strength and a reduced need for ventilation compared to IVIg, representing a significant advancement in treatment options.

In July 2022, ArchiMed SAS, a France-based investment company specializing in the healthcare industry, acquired Natus Medical Incorporated for $1.1 billion. This acquisition aims to strengthen ArchiMed SAS's position in neurodiagnostic devices while expanding its healthcare portfolio. By leveraging Natus' expertise and product offerings, the company seeks to drive innovation and growth in the neurodiagnostic sector. Natus Medical Incorporated, a US-based medical device company, focuses on designing and manufacturing medical devices for screening, diagnosing, and treating neurological disorders.

Major players in the guillain-barre syndrome market are Pfizer Inc., Roche AG, Thermo Fisher Scientific Inc., AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., Annexon Inc., Immunovant Inc., CSL Behring LLC, Hansa Biopharma AB, NeuLine Health Inc., Ridge Diagnostics Inc., Deymed Diagnostic LLC, and VYVGART Hytrulo.

North America was the largest region in the guillain-barre syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in guillain-barre syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the guillain-barre syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The guillain-barre syndrome market consists of revenues earned by entities by providing services such as plasma exchange (plasmapheresis), intravenous immunoglobulin (IVIG) therapy, neurological diagnostic tests, and supportive care treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The guillain-barre syndrome market also includes sales of pharmaceutical drugs, immunotherapies, and diagnostic tests. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Guillain-Barre Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on guillain-barre syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for guillain-barre syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The guillain-barre syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP); Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP); Miller Fisher Syndrome (MFS); Acute Motor Axonal Neuropathy (AMAN); Other Types
• 2) By Therapeutics: Intravenous Immunoglobulin (IVIG); Plasma Exchange; Other Therapeutics
• 3) By Route Of Administration: Parenteral; Oral
• 4) By End User: Hospitals; Clinics; Diagnostic Centers; Other End Users
• Subsegments:
• 1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP; AIDP with Autonomic Involvement
• 2) By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Progressive CIDP; Relapsing-Remitting CIDP; Multifocal CIDP
• 3) By Miller Fisher Syndrome (MFS): Classical MFS; MFS With Ataxia; MFS With Ophthalmoplegia
• 4) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN; AMAN with Respiratory Involvement
• 5) By Other Types: Acute Sensory Ganglionopathy; Variants With Cranial Nerve Involvement; Bickerstaff Brainstem Encephalitis
• Companies Mentioned: Pfizer Inc.; Roche AG; Thermo Fisher Scientific Inc.; AstraZeneca PLC; GSK plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Guillain-Barre Syndrome Market Characteristics

3. Guillain-Barre Syndrome Market Trends And Strategies

4. Guillain-Barre Syndrome Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Guillain-Barre Syndrome Growth Analysis And Strategic Analysis Framework

• 5.1. Global Guillain-Barre Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Guillain-Barre Syndrome Market Growth Rate Analysis
• 5.4. Global Guillain-Barre Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Guillain-Barre Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Guillain-Barre Syndrome Total Addressable Market (TAM)

6. Guillain-Barre Syndrome Market Segmentation

• 6.1. Global Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
• Miller Fisher Syndrome (MFS)
• Acute Motor Axonal Neuropathy (AMAN)
• Other Types
• 6.2. Global Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Immunoglobulin (IVIG)
• Plasma Exchange
• Other Therapeutics
• 6.3. Global Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Oral
• 6.4. Global Guillain-Barre Syndrome Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Diagnostic Centers
• Other End Users
• 6.5. Global Guillain-Barre Syndrome Market, Sub-Segmentation Of Acute Inflammatory Demyelinating Polyneuropathy (AIDP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classical AIDP
• AIDP with Autonomic Involvement
• 6.6. Global Guillain-Barre Syndrome Market, Sub-Segmentation Of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Progressive CIDP
• Relapsing-Remitting CIDP
• Multifocal CIDP
• 6.7. Global Guillain-Barre Syndrome Market, Sub-Segmentation Of Miller Fisher Syndrome (MFS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classical MFS
• MFS With Ataxia
• MFS With Ophthalmoplegia
• 6.8. Global Guillain-Barre Syndrome Market, Sub-Segmentation Of Acute Motor Axonal Neuropathy (AMAN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classical AMAN
• AMAN with Respiratory Involvement
• 6.9. Global Guillain-Barre Syndrome Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Sensory Ganglionopathy
• Variants With Cranial Nerve Involvement
• Bickerstaff Brainstem Encephalitis

7. Guillain-Barre Syndrome Market Regional And Country Analysis

• 7.1. Global Guillain-Barre Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Guillain-Barre Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Guillain-Barre Syndrome Market

• 8.1. Asia-Pacific Guillain-Barre Syndrome Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Guillain-Barre Syndrome Market

• 9.1. China Guillain-Barre Syndrome Market Overview
• 9.2. China Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Guillain-Barre Syndrome Market

• 10.1. India Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Guillain-Barre Syndrome Market

• 11.1. Japan Guillain-Barre Syndrome Market Overview
• 11.2. Japan Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Guillain-Barre Syndrome Market

• 12.1. Australia Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Guillain-Barre Syndrome Market

• 13.1. Indonesia Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Guillain-Barre Syndrome Market

• 14.1. South Korea Guillain-Barre Syndrome Market Overview
• 14.2. South Korea Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Guillain-Barre Syndrome Market

• 15.1. Western Europe Guillain-Barre Syndrome Market Overview
• 15.2. Western Europe Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Guillain-Barre Syndrome Market

• 16.1. UK Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Guillain-Barre Syndrome Market

• 17.1. Germany Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Guillain-Barre Syndrome Market

• 18.1. France Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Guillain-Barre Syndrome Market

• 19.1. Italy Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Guillain-Barre Syndrome Market

• 20.1. Spain Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Guillain-Barre Syndrome Market

• 21.1. Eastern Europe Guillain-Barre Syndrome Market Overview
• 21.2. Eastern Europe Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Guillain-Barre Syndrome Market

• 22.1. Russia Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Guillain-Barre Syndrome Market

• 23.1. North America Guillain-Barre Syndrome Market Overview
• 23.2. North America Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Guillain-Barre Syndrome Market

• 24.1. USA Guillain-Barre Syndrome Market Overview
• 24.2. USA Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Guillain-Barre Syndrome Market

• 25.1. Canada Guillain-Barre Syndrome Market Overview
• 25.2. Canada Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Guillain-Barre Syndrome Market

• 26.1. South America Guillain-Barre Syndrome Market Overview
• 26.2. South America Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Guillain-Barre Syndrome Market

• 27.1. Brazil Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Guillain-Barre Syndrome Market

• 28.1. Middle East Guillain-Barre Syndrome Market Overview
• 28.2. Middle East Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Guillain-Barre Syndrome Market

• 29.1. Africa Guillain-Barre Syndrome Market Overview
• 29.2. Africa Guillain-Barre Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Guillain-Barre Syndrome Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Guillain-Barre Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Guillain-Barre Syndrome Market Competitive Landscape And Company Profiles

• 30.1. Guillain-Barre Syndrome Market Competitive Landscape
• 30.2. Guillain-Barre Syndrome Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis

31. Guillain-Barre Syndrome Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Merck & Co. Inc.
• 31.3. Baxter International Inc.
• 31.4. Biogen Inc.
• 31.5. Horizon Therapeutics
• 31.6. Octapharma AG
• 31.7. Kedrion S.p.A.
• 31.8. Annexon Inc.
• 31.9. Immunovant Inc.
• 31.10. CSL Behring LLC
• 31.11. Hansa Biopharma AB
• 31.12. NeuLine Health Inc.
• 31.13. Ridge Diagnostics Inc.
• 31.14. Deymed Diagnostic LLC
• 31.15. VYVGART Hytrulo

32. Global Guillain-Barre Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Guillain-Barre Syndrome Market

34. Recent Developments In The Guillain-Barre Syndrome Market

35. Guillain-Barre Syndrome Market High Potential Countries, Segments and Strategies

• 35.1 Guillain-Barre Syndrome Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Guillain-Barre Syndrome Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Guillain-Barre Syndrome Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer